Delving into the Latest Updates on Shanghai Minwei Biotechnology Co., Ltd with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Nervous System Diseases

Digestive System Disorders

Fc fusion protein

Synthetic peptide

siRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	9
Nervous System Diseases	2

Top 5 Drug Type	Count

Fc fusion protein	4
Synthetic peptide	2
Antibody	1
Fusion protein	1
Antibody oligonucleotide conjugates	1

Top 5 Target	Count

GCGR x GIPR x GLP-1R	2
FGF21R x GCGR x GIPR x GLP-1R	1
FGF21R x GIPR x GLP-1R	1
GIPR x GLP-1R	1

主要目的：评估 MWN109 注射液在中国非糖尿病的超重或肥胖参与者中多次给药的安全性、耐受性。次要目的：评估MWN109注射液在中国非糖尿病的超重或肥胖参与者中多次给药的药代动力学特征。探索性目的：评估MWN109注射液在中国非糖尿病的超重或肥胖参与者中多次给药的药效学特征。评估MWN109注射液在中国非糖尿病的超重或肥胖参与者中多次给药的免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of MWN109 injection after multiple administration in Chinese non-diabetic overweight or obese participants. Secondary objective: To evaluate the pharmacokinetic characteristics of MWN109 injection after multiple administration in Chinese non-diabetic overweight or obese participants. Exploratory objective: To evaluate the pharmacodynamic characteristics of MWN109 injection after multiple administration in Chinese non-diabetic overweight or obese participants. To evaluate the immunogenicity of MWN109 injection after multiple administration in Chinese non-diabetic overweight or obese participants.

Start Date13 Jul 2025

Sponsor / Collaborator

Shanghai Minwei Biotechnology Co., Ltd

CTR20252244

/ RecruitingPhase 1

评估 MWN109 片在中国研究参与者中单、多次口服给药的安全性、耐受性、药代动力学和进餐时间影响的随机、双盲、安慰剂对照 I 期临床研究

[Translation] A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and meal timing effects of single and multiple oral administrations of MWN109 tablets in Chinese study participants

主要目的：评估 MWN109 片在中国参与者中单、多次给药的安全性、耐受性。次要目的：评估 MWN109 片及其辅料沙波立沙钠（SNAC）在中国参与者中单、多次给药的药代动力学特征。评价进餐时间对 MWN109 片药代动力学特征的影响。探索性目的：初步评估 MWN109 片在中国参与者中的药效学特征。初步评估 MWN109 片在中国参与者中的免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of MWN109 tablets in Chinese participants after single and multiple administrations. Secondary objective: To evaluate the pharmacokinetic characteristics of MWN109 tablets and its excipient sabolic steroid sodium (SNAC) in Chinese participants after single and multiple administrations. To evaluate the effect of meal time on the pharmacokinetic characteristics of MWN109 tablets. Exploratory objective: To preliminarily evaluate the pharmacodynamic characteristics of MWN109 tablets in Chinese participants. To preliminarily evaluate the immunogenicity of MWN109 tablets in Chinese participants.

Start Date26 Jun 2025

Sponsor / Collaborator

Shanghai Minwei Biotechnology Co., Ltd

CTR20252387

/ RecruitingPhase 1

评估 MWX203 注射液在中国健康受试者中单次皮下给药的安全性、耐受性、药代动力学的随机、双盲、安慰剂对照 I 期临床研究

[Translation] A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of MWX203 injection after a single subcutaneous administration in healthy Chinese subjects

主要目的： 1、评估MWX203注射液在中国健康受试者中单次给药的安全性、耐受性。次要目的： 1、评估 MWX203 注射液在中国健康受试者中单次给药的药代动力学； 2、评估 MWX203 在中国健康受试者中单次给药的免疫原性。探索性目的： 1、评估 MWX203 注射液在中国健康受试者中单次给药的药效学； 2、评估 MWX203 可能的代谢产物。

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of a single dose of MWX203 injection in healthy Chinese subjects. Secondary objectives: 1. To evaluate the pharmacokinetics of a single dose of MWX203 injection in healthy Chinese subjects; 2. To evaluate the immunogenicity of a single dose of MWX203 in healthy Chinese subjects. Exploratory objectives: 1. To evaluate the pharmacodynamics of a single dose of MWX203 injection in healthy Chinese subjects; 2. To evaluate the possible metabolites of MWX203.

Start Date25 Jun 2025

Sponsor / Collaborator

Shanghai Minwei Biotechnology Co., Ltd

100 Clinical Results associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

100 Deals associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

100 Translational Medicine associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

6

2

Phase 1

Phase 2

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MWN-109 ( GCGR x GIPR x GLP-1R )	Obesity More	Phase 2
MWN-101 ( GCGR x GIPR x GLP-1R )	Obesity More	Phase 2
MWN105 ( FGF21R x GIPR x GLP-1R )	Nonalcoholic Steatohepatitis More	Phase 1
MWN-103 ( FGF21R x GCGR x GIPR x GLP-1R )	Obesity More	Phase 1
MWX-203	Hyperlipidemias More	Preclinical